Table 1.
Patient Characteristics
| Rituximab Sensitive (N=48) |
Rituximab Refractory (N=21) |
Total (N=69) |
p value | |
|---|---|---|---|---|
| Age | 0·791 | |||
| Median (years) | 67.5 | 66 | 67 | |
| Range (years) | (51-86) | (44-85) | (44-86) | |
| Gender | 0·902 | |||
| female | 13 (27·1%) | 6 (28·6%) | 19 (27·5%) | |
| male | 35 (72·9%) | 15 (71·4%) | 50 (72·5%) | |
| Performance Score | 0·813 | |||
| 0 | 32 (66·7%) | 12 (57·1%) | 44 (63·8%) | |
| 1 | 14 (29·2%) | 8 (38·1%) | 22 (31·9%) | |
| 2 | 2 (4·2%) | 1 (4·8%) | 3 (4·3%) | |
| Number of Previous Treatments | <0·00013 | |||
| Mean (SD) | 2·1 (1·51) | 3·6 (1·66) | 2·5 (1·70) | |
| Median | 2·0 | 3·0 | 2·0 | |
| Range | (1-9) | (1-9) | (1-9) | |
| Previous Initial Therapy | 0·833 | |||
| R-CHOP | 33 (68·8%) | 18 (85·7%) | 51 (73·9%) | |
| R-HyperCVAD | 5 (10·4%) | 1 (4·8%) | 6 (8·7%) | |
| R-DHAP | 1 (2%) | 0 | 1 (1·4%) | |
| Cladribine + rituximab | 5 (10·4%) | 1 (4·8%) | 6 (8·7%) | |
| Other | 4 (8·3%) | 1 (4·8%) | 5 (7·2%) | |
| Previous Stem Cell Transplant | 0·432 | |||
| Yes | 16 (33·3%) | 5 (23·8%) | 21 (30·4%) | |
| No | 32 (66·7%) | 16 (76·2%) | 48 (69·6%) | |
| Previous Radioimmunotherapy | 0·583 | |||
| Yes | 2 (4·2%) | 2 (9·5%) | 4 (5·8%) | |
| No | 46 (95·8%) | 19 (90·5%) | 65 (94·2%) | |
| Previous Radiation Therapy | 0·062 | |||
| Yes | 10 (20·8%) | 9 (42·9%) | 19 (27·5%) | |
| No | 38 (79·2%) | 12 (57·1%) | 50 (72·5%) |
1
Kruskal Wallis
2
Chi-Square
3
Fisher Exact
R-CHOP – rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone. R-HyperCVAD – rituximab, cyclophosphamide, vincristine, doxorubicin, dexamethasone, methotrexate, cytarabine. R-DHAP – rituximab, dexamethasone, cytarabine, cisplatin.